Targeted beta therapy of prostate cancer with (177)Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

PURPOSE: Chimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Mei-Chun, Tse, Brian W. C., Fletcher, Nicholas L., Houston, Zachary H., Lund, Maria, Volpert, Marianna, Stewart, Chelsea, Sokolowski, Kamil A., Jeet, Varinder, Thurecht, Kristofer J., Campbell, Douglas H., Walsh, Bradley J., Nelson, Colleen C., Russell, Pamela J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206480/
https://www.ncbi.nlm.nih.gov/pubmed/32382920
http://dx.doi.org/10.1186/s13550-020-00637-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206480/
https://www.ncbi.nlm.nih.gov/pubmed/32382920
http://dx.doi.org/10.1186/s13550-020-00637-x

Ejemplares similares